Adis, Auckland, New Zealand.
Am J Clin Dermatol. 2012 Oct 1;13(5):349-54. doi: 10.2165/11209100-000000000-00000.
Ipilimumab (Yervoy™), a recombinant monoclonal antibody targeted at cytotoxic T-lymphocyte-associated antigen 4, is approved for the treatment of advanced melanoma. In a placebo-controlled trial in previously treated patients with advanced melanoma, ipilimumab, without or with an investigational glycoprotein (gp) 100 peptide vaccine, was associated with significantly longer median overall survival than gp100 peptide vaccine monotherapy. The risk of death relative to the gp100 peptide vaccine was reduced by 34% with ipilimumab monotherapy and by 32% with ipilimumab plus gp100 peptide vaccine. Overall survival did not differ significantly between treatment with ipilimumab monotherapy and ipilimumab plus gp100 peptide vaccine. Novel immune-related events that are not typical of other anticancer agents, most commonly dermatologic and gastrointestinal disorders, can occur with ipilimumab, necessitating specific monitoring and management protocols.
依匹单抗（Yervoy™），一种针对细胞毒性 T 淋巴细胞相关抗原 4 的重组单克隆抗体，被批准用于治疗晚期黑色素瘤。在一项先前治疗的晚期黑色素瘤患者的安慰剂对照试验中，与 gp100 肽疫苗单药治疗相比，依匹单抗（无论是否联合研究性糖蛋白 [gp] 100 肽疫苗）与更长的中位总生存期相关。与 gp100 肽疫苗相比，依匹单抗单药治疗和依匹单抗联合 gp100 肽疫苗治疗的死亡风险分别降低了 34%和 32%。依匹单抗单药治疗与依匹单抗联合 gp100 肽疫苗治疗的总生存期无显著差异。与其他抗癌药物不同的新型免疫相关事件，最常见的是皮肤和胃肠道疾病，可能与依匹单抗有关，需要特定的监测和管理方案。
